A phase 3 trial subgroup analysis found that adding pembrolizumab to adjuvant chemotherapy may improve disease-free survival in patients with mismatch repair-deficient endometrial cancer, a population at...
A randomized trial found that radiation therapy alone provides better progression-free survival and fewer acute toxicities than chemoradiation for women with localized recurrent endometrial cancer.
This phase 3 study demonstrated that roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is noninferior to rHuEPO-α in improving hemoglobin levels for chemotherapy-induced anemia,...
Neoadjuvant nivolumab plus ipilimumab demonstrated improved event-free survival, higher pathologic complete response rates, and lower toxicity compared with chemotherapy in patients with resectable...
New findings from the Women’s Health Initiative trials provide long-term insights into the effects of hormone therapy regimens on ovarian and endometrial cancer incidence and mortality.
A large multicenter study suggests that artificial intelligence-supported mammography screening can improve breast cancer detection rates without increasing recall rates, addressing key challenges in...
A recent study assessed cervical cancer mortality trends among US women younger than 25 from 1992 to 2021, highlighting changes in mortality rates following the widespread use of the HPV vaccine.
Researchers developed a cross-sectional survey to understand the public and provider awareness of postmenopausal bleeding as a symptom of endometrial cancer.
A decade-long follow-up of a landmark trial examining survival outcomes in patients with advanced melanoma treated with nivolumab plus ipilimumab, nivolumab monotherapy, or ipilimumab monotherapy, provides...
A recent phase 3 study found that venetoclax-obinutuzumab improves progression-free survival and quality of life compared with chlorambucil-obinutuzumab in patients with untreated chronic lymphocytic...
